581 related articles for article (PubMed ID: 31453630)
41. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.
Sausville EA; Eddy JL; Makuch RW; Fischmann AB; Schechter GP; Matthews M; Glatstein E; Ihde DC; Kaye F; Veach SR
Ann Intern Med; 1988 Sep; 109(5):372-82. PubMed ID: 3408055
[TBL] [Abstract][Full Text] [Related]
42. Naïve/memory T-cell phenotypes in leukemic cutaneous T-cell lymphoma: Putative cell of origin overlaps disease classification.
Horna P; Moscinski LC; Sokol L; Shao H
Cytometry B Clin Cytom; 2019 May; 96(3):234-241. PubMed ID: 30328260
[TBL] [Abstract][Full Text] [Related]
43. New aspects of the clinicopathological features and treatment of mycosis fungoides and Sézary syndrome.
Furue M; Kadono T
J Dermatol; 2015 Oct; 42(10):941-4. PubMed ID: 26432429
[TBL] [Abstract][Full Text] [Related]
44. [Clinicopathological differential diagnosis of mycosis fungoides/Sézary syndrome from the cutaneous type of adult T-cell leukemia/lymphoma].
Johno M; Ono T
Nihon Rinsho; 2000 Mar; 58(3):660-4. PubMed ID: 10741142
[TBL] [Abstract][Full Text] [Related]
45. Expression of Sézary Biomarkers in the Blood of Patients with Erythrodermic Mycosis Fungoides.
Hurabielle C; Michel L; Ram-Wolff C; Battistella M; Jean-Louis F; Beylot-Barry M; d'Incan M; Bensussan A; Bagot M
J Invest Dermatol; 2016 Jan; 136(1):317-20. PubMed ID: 26763453
[No Abstract] [Full Text] [Related]
46. Using molecular biologic analysis of T-cell receptor gene rearrangements to stage cutaneous T-cell lymphoma.
Wood GS
Arch Dermatol; 1998 Feb; 134(2):221-3. PubMed ID: 9487215
[No Abstract] [Full Text] [Related]
47. A new molecular paradigm in mycosis fungoides and Sézary syndrome.
Elenitoba-Johnson KS; Wilcox R
Semin Diagn Pathol; 2017 Jan; 34(1):15-21. PubMed ID: 28024703
[TBL] [Abstract][Full Text] [Related]
48. Retrospective 5-year review of 131 patients with mycosis fungoides and Sézary syndrome seen at the National Skin Centre, Singapore.
Tan ES; Tang MB; Tan SH
Australas J Dermatol; 2006 Nov; 47(4):248-52. PubMed ID: 17034466
[TBL] [Abstract][Full Text] [Related]
49. Sézary cell count in exfoliative dermatitis.
Duangurai K; Piamphongsant T; Himmungnan T
Int J Dermatol; 1988 May; 27(4):248-52. PubMed ID: 2968960
[TBL] [Abstract][Full Text] [Related]
50. Large cell transformation of Sézary syndrome. A conventional and molecular cytogenetic study.
So CC; Wong KF; Siu LL; Kwong YL
Am J Clin Pathol; 2000 Jun; 113(6):792-7. PubMed ID: 10874879
[TBL] [Abstract][Full Text] [Related]
51. Folliculotropic mycosis fungoides (stage IIA) progressing to Sézary syndrome: a case report.
Agar N; Whittaker SJ
Br J Dermatol; 2008 Nov; 159(5):1197-9. PubMed ID: 18764843
[TBL] [Abstract][Full Text] [Related]
52. Leu-8/CD7 antigen expression by CD3+ T cells: comparative analysis of skin and blood in mycosis fungoides/Sézary syndrome relative to normal blood values.
Wood GS; Hong SR; Sasaki DT; Abel EA; Hoppe RT; Warnke RA; Morhenn VB
J Am Acad Dermatol; 1990 Apr; 22(4):602-7. PubMed ID: 1690762
[TBL] [Abstract][Full Text] [Related]
53. A High Programmed Cell Death Protein 1 Hormone Receptor Score on Skin Biopsy is Associated with Sézary Syndrome Diagnosis: A Study of 91 Patients with Erythroderma.
Luherne C; Menguy S; Ferte T; Beylot-Barry M; Seneschal J; Milpied B; Vial JP; Gros A; Amintas S; Vergier B; Pham-Ledard A
Acta Derm Venereol; 2022 Sep; 102():adv00773. PubMed ID: 35758515
[TBL] [Abstract][Full Text] [Related]
54. Mycosis fungoides and Sézary syndrome.
Hwang ST; Janik JE; Jaffe ES; Wilson WH
Lancet; 2008 Mar; 371(9616):945-57. PubMed ID: 18342689
[TBL] [Abstract][Full Text] [Related]
55. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential.
Ballabio E; Mitchell T; van Kester MS; Taylor S; Dunlop HM; Chi J; Tosi I; Vermeer MH; Tramonti D; Saunders NJ; Boultwood J; Wainscoat JS; Pezzella F; Whittaker SJ; Tensen CP; Hatton CS; Lawrie CH
Blood; 2010 Aug; 116(7):1105-13. PubMed ID: 20448109
[TBL] [Abstract][Full Text] [Related]
56. Differential expression of programmed death-1 (PD-1) in Sézary syndrome and mycosis fungoides.
Cetinözman F; Jansen PM; Vermeer MH; Willemze R
Arch Dermatol; 2012 Dec; 148(12):1379-85. PubMed ID: 23247480
[TBL] [Abstract][Full Text] [Related]
57. TOX expression in different subtypes of cutaneous lymphoma.
Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
[TBL] [Abstract][Full Text] [Related]
58. Analysis of beta, gamma, and delta T-cell receptor genes in mycosis fungoides and Sezary syndrome.
Whittaker SJ; Smith NP; Jones RR; Luzzatto L
Cancer; 1991 Oct; 68(7):1572-82. PubMed ID: 1654197
[TBL] [Abstract][Full Text] [Related]
59. Transformation of Sézary syndrome into CD30+ anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity.
Nevet MJ; Zuckerman T; Sahar D; Bergman R
Am J Dermatopathol; 2015 Jan; 37(1):73-7. PubMed ID: 25548993
[TBL] [Abstract][Full Text] [Related]
60. Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome.
Scarisbrick JJ; Woolford AJ; Calonje E; Photiou A; Ferreira S; Orchard G; Russell-Jones R; Whittaker SJ
J Invest Dermatol; 2002 Mar; 118(3):493-9. PubMed ID: 11874489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
